Navigation Links
New malaria vaccines roadmap targets next generation products by 2030

WASHINGTON, DC - 14 November 2013 The world should aim to have vaccines which reduce malaria cases by 75 percent, and are capable of eliminating malaria, licensed by 2030, according to the updated 2013 Malaria Vaccine Technology Roadmap, launched today. This new target comes in addition to the original 2006 Roadmap's goal of having a licensed vaccine against Plasmodium falciparum malaria, the most deadly form of the disease, for children under 5 years of age in sub-Saharan Africa by 2015.

"Safe, effective, affordable vaccines could play a critical role in defeating malaria," said Dr Robert D. Newman, Director of the World Health Organization's (WHO) Global Malaria Programme. "Despite all the recent progress countries have made, and despite important innovations in diagnostics, drugs and vector control, the global burden of malaria remains unacceptably high."

The most recent figures by WHO indicate that malaria causes an estimated 660,000 deaths each year from 219 million cases of illness. Scale-up of WHO recommended malaria control measures has been associated with a 26 percent reduction in the global malaria death rate over the last decade. Effective malaria vaccines could be an important complement to existing measures, if they can be successfully developed.

Final results from Phase III trials of the most advanced vaccine candidate, RTS,S/AS01, will be available by 2015. Depending on the final trial results, and depending on the outcome of the regulatory review by the European Medicines Agency, a WHO recommendation for use and subsequent prequalification of this first vaccine could occur in late 2015.

The new roadmap, launched today at the annual conference of the American Society of Tropical Medicine & Hygiene in Washington, DC and also announced in a letter published in The Lancet, aims to identify where additional funding and activities will be particularly key in developing second generation malaria vaccines both for protection against malaria disease and for malaria elimination. These include next-generation vaccines that target both Plasmodium falciparum and Plasmodium vivax species of malaria.

"The new vaccines should show at least 75 percent efficacy against clinical malaria, be suitable for use in in all malaria-endemic areas, and be licensed by 2030," says Dr Jean-Marie Okwo Bele, Director of WHO's Department of Immunization, Vaccines and Biologicals. "The roadmap also sets a target for malaria vaccines that reduce transmission of the parasite."

The 2013 Malaria Vaccine Technology Roadmap cites several reasons for the update, among them changing malaria epidemiology associated with the successful scale-up of malaria control measures in the last decade, a renewed focus on malaria elimination and eradication in addition to the ongoing need to sustain malaria control activities, and new technological innovations since 2006 including promising early work on so-called transmission-blocking malaria vaccines.

WHO lists 27 malaria vaccine candidates currently in clinical trials, with most in early stages of testing; RTS,S/AS01 is the only one currently in late-stage development.

The roadmap's vision centres on developing safe and effective vaccines against Plasmodium falciparum and Plasmodium vivax that prevent disease and death and prevent transmission to enable malaria eradication, and is built around two strategic goals:

  • Development of malaria vaccines with protective efficacy of at least 75 percent against clinical malaria suitable for administration to appropriate at-risk groups in malaria-endemic areas.
  • Development of malaria vaccines that reduce transmission of the parasite and thereby substantially reduce the incidence of human malaria infection. This will enable elimination in multiple settings. Vaccines to reduce transmission should be suitable for administration in mass campaigns.


Contact: Dr. Vasee Moorthy

Related biology news :

1. Holograms offer hope in fight against malaria, study suggests
2. CWRU grants Disease Diagnostic Group option on malaria diagnostic device
3. NIH fellowship helps researcher fight malaria, understand mosquito immunity
4. Hand-held device cheaply, quickly diagnosis malaria
5. Quest for edible malarial vaccine leads to other potential medical uses for algae
6. Early warning system provides 4-month forecast of malaria epidemics in northwest India
7. New method for researching understudied malaria-spreading mosquitoes
8. New approach alters malaria maps
9. Young malaria parasites refuse to take their medicine, may explain emerging drug resistance
10. MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech
11. Penn team mimicking a natural defense against malaria to develop new treatments
Post Your Comments:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
Breaking Biology Technology: